3 results
The primary objective of this study is to assess whether abelacimab is non-inferior to dalteparin for preventing VTE recurrence through 6 monthspost randomization in patients with GI or GU cancer and recently diagnosed VTE. If non-inferiority is…
The primary objective of this study is to assess whether abelacimab is non-inferior to apixaban for preventing VTE recurrence at 6 months postrandomization in patients with cancer and recently diagnosed VTE. If noninferiority is demonstrated, then…
The objective of this study is to evaluate the (cost-)effectiveness of reduced noradrenaline in patients with CS by using a lower MAP target of >= 55 mmHg, compared to usual care. We hypothesize that reduced use of noradrenaline will improve…